CSBR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CSBR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Champions Oncology's yield on cost for the quarter that ended in Jan. 2024 was 0.00.
The historical rank and industry rank for Champions Oncology's 5-Year Yield-on-Cost % or its related term are showing as below:
For the Biotechnology subindustry, Champions Oncology's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Champions Oncology's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Champions Oncology's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Champions Oncology is calculated as
Yield-on-Cost | = | Dividend Yield % | * | (1 | + | Dividend Growth Rate)^5 |
Champions Oncology (NAS:CSBR) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Thank you for viewing the detailed overview of Champions Oncology's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.
Daniel Newman Mendelson | director | COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR, SUITE 900, BETHESDA MD 20817 |
Ronnie Morris | director, officer: President | 855 N. WOLFE STREET, SUITE 619, BALTIMORE MD 21205 |
Philip P. Breitfeld | director | ONE UNIVERSITY PLAZA, SUITE 307, HACKENSACK NJ 07601 |
New Enterprise Associates 14, L.p. | 10 percent owner | 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
Neeraj Agrawal | 10 percent owner | ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210 |
Roger H Lee | 10 percent owner | ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210 |
Michael Maurice Brown | 10 percent owner | ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210 |
Battery Management Corp. | 10 percent owner | ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210 |
R David Tabors | 10 percent owner | ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210 |
Jesse Feldman | 10 percent owner | ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210 |
Joel Ackerman | director, officer: Chief Executive Officer | COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR SUITE 900, BETHESDA MD 20817 |
Patrick J Kerins | 10 percent owner | |
Ryan D Drant | 10 percent owner | 1119 ST PAUL STREET, BALTIMORE MD 21202 |
Nea 14 Gp, Ltd | 10 percent owner | 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
Nea Partners 14, L.p. | 10 percent owner | 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
From GuruFocus
By ACCESSWIRE • 11-02-2023
By ACCESSWIRE ACCESSWIRE • 04-17-2023
By ACCESSWIRE ACCESSWIRE • 01-04-2022
By ACCESSWIRE ACCESSWIRE • 05-31-2022
By ACCESSWIRE • 10-17-2023
By ACCESSWIRE ACCESSWIRE • 07-14-2021
By ACCESSWIRE ACCESSWIRE • 01-05-2021
By ACCESSWIRE ACCESSWIRE • 12-08-2020
By ACCESSWIRE ACCESSWIRE • 03-05-2021
By ACCESSWIRE • 07-21-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.